Immunotherapy Platform ShennonBio’s proprietary single-cell profiling platform enables high-throughput functional immune cell analysis, presenting a compelling selling point for companies developing immunotherapies who need deeper mechanistic insights to optimize therapies for solid tumors and autoimmune diseases.

Strategic Funding Recent oversubscribed seed funding of 13M from DCVC, Foundation Capital, and AV8 signals strong investor confidence and potential for rapid product development, enabling accelerated outreach to pharma partners seeking advanced immunoprofiling capabilities.

San Francisco Footprint Headquartered near UCSF Mission Bay with a lean team (11-50 employees), ShennonBio offers proximity to premier academic and clinical ecosystems, ideal for collaborations, pilot studies, and access to clinical researchers for validation.

Commercial Readiness With reported revenue in the mid-teens of millions and a funded seed round, the company demonstrates early market traction and financial bandwidth to support pilot programs, proofs of concept, and co-development deals with larger biotech and diagnostic players.

Industry Fit Target customers likely include large biopharma, contract research organizations, and diagnostic firms seeking scalable immune profiling and antigen-immune interaction data to de-risk immunotherapy programs and inform patient stratification strategies.